AIM Rule 26
The following information is being disclosed for the purposes of Rule 26 of the AIM Rules for Companies.
Country of Incorporation and Main Country of Operation
Country of Incorporation: England and Wales
Company Registration Number: 3929567
Main Country of Operation: France
One Bartholomew Close, London, EC1A 7BL UK
Please click below for details of ImmuPharma’s Corporate Governance procedure
US Biotech Showcase Event – January 2021
Click on the link above for the Immupharma plc Annual Report 2019 .
Please note the file may take a few minutes to open.
It is recommended you save the report on your hard drive; download and then right click on the photo and choose “Save As” and then save it on your computer before you open it.
Annual Report December 2018
Annual Report December 2017
Annual Report December 2016
Annual Report December 2015
Annual Report December 2014
Annual Report December 2013
Annual Report December 2012
Annual Report December 2011
Annual Report December 2010
Annual Report December 2009
Annual Report December 2008
Annual Report December 2007
Annual Report March 2006
Latest Interim Report
NOTICE OF ANNUAL GENERAL MEETING ON 18 JUNE 2020 @ 10.30 AM
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2019 has been posted to shareholders.
These documents are available, in electronic form, for download on the Company’s website www.immupharma.co.uk
ImmuPharma’s Annual General Meeting (AGM) will be held on Thursday, 18 June 2020 @ 10.30am (BST) at: 52 Grosvenor Gardens, London SW1W 0AU
We note the current issues surrounding COVID-19 (coronavirus) and the rapidly developing public health guidance in the UK at the time of writing. This includes the stringent requirements announced on 23 March 2020, which require UK nationals to stay at home except in tightly defined circumstances (which do not include attending an AGM), the social distancing and shielding guidance for those over the age of 70 or with underlying medical conditions, and the ban on all non-essential travel. The health and safety of our shareholders and colleagues is always our utmost priority.
As it is no longer possible to hold the AGM in the way that the Board had planned, we cannot allow shareholders to attend in person. Any shareholders attempting to gain access to the AGM will be excluded from the meeting on grounds of public safety. In the light of the above, we strongly encourage you to consider ensuring your vote is counted by submission of the proxy by post as detailed in the Notice of Annual General Meeting.
Please contact Lisa Baderoon at email@example.com if you have any questions regarding the AGM.
Nominated Adviser ‘NOMAD”
SPARK Advisory Partners Limited
5 St John’s Ln, Clerkenwell, London EC1M 4BH
Tel +44 20 3368 3550
Stanford Capital Partners Limited
15-17 Eldon Street, London EC2M 7LD
Tel +44 203 815 8880
Si Capital Limited
43 Brook Street, Mayfair, London W1K 4HJ
Tel +44 203 841 6178
Bircham Dyson Bell, One Bartholomew Close, London EC1A 7BL U.K.
Nexia Smith & Williamson Chartered Accountants
25 Moorgate London EC2R 6AY, UK
Royal Bank of Scotland plc
62/63 Threadneedle Street, London EC2R 8LA, UK
Computershare Investor Services PLC, PO Box 82, The Pavilions, Bridgewater Road, Bristol, BS99 7NH, UK
Details of Any Other Exchanges or Trading Platforms
ImmuPharma has a dual listing with Euronext Growth Brussels (Euronext) and shares can be traded under the ticker ‘ALIMM’ from 19 December 2019 when admission to Euronext takes effect. In addition to AIM, this dual listing on Euronext allows ImmuPharma to join the number one European stock exchange for Life Sciences and the world’s second biggest for biotech companies after the United States.
The Company’s shares are also traded in Germany. ‘Tradegate’ which is an open market listing on the Berlin Exchange and the ‘third segment’ of the Stuttgart Stock Exchange.
Number of Securities In Issue and Significant Shareholders
ImmuPharma has 250,221,2975 ordinary shares of 10p each in issue, each of which entitles the holder to cast one vote in general meetings. The Company does not hold any Ordinary Shares in treasury. As at 7 December 2020, major shareholders that hold more than 3% of the share capital of ImmuPharma, confirmed through a TR1, are detailed below:
|Number of Ordinary 10p shares||% of issued share capital|
|*Total ImmuPharma plc Directors
Lanstead Capital Investors LP
|Total Issued Share Capital||250,221,297||100%|
|*The breakdown of the Director’s holding is:|
|Robert Zimmer (including related party)
(President and Chief Science Officer)
(Chief Executive Officer and Co-founder)
|Franco di Muzio
(Senior Non-Executive Director)
|Dr Stéphane Méry
As far as the Company is aware, the percentage of ImmuPharma’s issued share capital that is not in public hands is approximately 12.5%. This percentage comprises the holdings of Directors only.
Immupharma is subject to the UK City Code on Takeovers and Mergers.
Details of any restrictions on the transfer of securities
There are no restrictions on the transfer of securities.
Presentations, circulars, Proxy Forms and Admission Document
Please click on the link below to access the Company’s current presentation
IMM Corporate Presentation (April 2020)
Please click here for the link to access the Company’s Notice of the 2020 Annual General Meeting
IMM Notice of the 2020 Annual General Meeting
Please click on the link below to access the Company’s Proxy Form
IMM Proxy Form: Annual General Meeting to be held on Thursday 18 June 2020
Please click on the link below to access the Company’s circulars
IMM Circular February 2016 Fundrasing
Please click on the link below to access the Company’s Proxy Forms
IMM Proxy Form February 2016 Fundraising
Please click on the link below to access the Company’s Admission Document (January 2006).
ImmuPharma Admission Document
Please click on the link below to access the Company’s ‘Information Note’ as required by the Euronext Growth Market Rules Book and Belgian financial regulations (17 November 2019)
Special rules apply when US persons (as defined in the United States securities laws) access this website. For US regulatory reasons, US residents and other US persons who reside outside the United States are not permitted to access this website. The company is not offering any securities or services in the United States or to residents of the United States through this website or otherwise. Please refer to our Disclaimer.
Last Updated: 25/01/2021